The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets

10.18632/oncotarget.8775

Saved in:

Bibliographic Details
Main Authors:	Chong, D.Q, Zhu, A.X
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Review
Published:	Impact Journals LLC 2020
Subjects:	B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib FGFR2 protein, human MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/180389
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-180389
record_format	dspace
spelling	sg-nus-scholar.10635-1803892023-11-01T08:19:49Z The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets Chong, D.Q Zhu, A.X DUKE-NUS MEDICAL SCHOOL B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib epidermal growth factor receptor FGFR2 protein, human fibroblast growth factor receptor 2 isocitrate dehydrogenase MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct carcinoma bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor 10.18632/oncotarget.8775 Oncotarget 7 29 46750-46767 2020-10-26T08:46:01Z 2020-10-26T08:46:01Z 2016 Review Chong, D.Q, Zhu, A.X (2016). The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets. Oncotarget 7 (29) : 46750-46767. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.8775 1949-2553 https://scholarbank.nus.edu.sg/handle/10635/180389 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Impact Journals LLC Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib epidermal growth factor receptor FGFR2 protein, human fibroblast growth factor receptor 2 isocitrate dehydrogenase MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct carcinoma bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor
spellingShingle	B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib epidermal growth factor receptor FGFR2 protein, human fibroblast growth factor receptor 2 isocitrate dehydrogenase MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct carcinoma bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor Chong, D.Q Zhu, A.X The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
description	10.18632/oncotarget.8775
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Chong, D.Q Zhu, A.X
format	Review
author	Chong, D.Q Zhu, A.X
author_sort	Chong, D.Q
title	The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
title_short	The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
title_full	The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
title_fullStr	The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
title_full_unstemmed	The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
title_sort	landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
publisher	Impact Journals LLC
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/180389
_version_	1781792379751104512

The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets

Similar Items